Brief: Helius Announces Positive Outcome Of The Portable Neuromodulation Stimulator Pons Stroke Registrational Program
21/07/2025 12:07
July 21 (Reuters) - Helius Medical Technologies Inc HSDT.O: HELIUS ANNOUNCES POSITIVE OUTCOME OF THE PORTABLE NEUROMODULATION STIMULATOR PONS® STROKE REGISTRATIONAL PROGRAM AND UPCOMING SUBMISSION TO FDA UNDER BREAKTHROUGH DESIGNATION HELIUS MEDICAL TECHNOLOGIES INC - STUDIES CONFIRM MINIMAL ADVERSE EVENTS WITH PONS THERAPY HELIUS MEDICAL TECHNOLOGIES: PLANNING TO FILE A SUBMISSION TO FDA FOR INDICATION IN STROKE DURING Q3 OF 2025 Source text: ID:nGNX4szG36 Further company coverage: HSDT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Solana Co
See all newsBrief: Solana Co Pursuant To Prospectus Supplement, May Offer Shares Of Common Stock Of Up To $250 Million From Time To Time
Brief: Solana: On May 12, Dane C. Andreeff Resigns As CEO, President And Board Member
Solana Co Q1 revenue surges on staking rewards
Brief: Solana Company (Nasdaq Hsdt) Appoints Madelene Gani As Chief Operating Officer And Deputy CFO To Lead Next Phase Of Growth
Solana Co Q4 revenue surges on staking rewards, swings to profit